Stifel on Cytokinetics (CYTK): 'We Think The Trial Likely Works, Positioning Afi As The Best/Only Drug Available For The Entire HCM Spectrum'
Tweet Send to a Friend
Stifel analyst James Condulis reiterated a Buy rating and $98.00 price target on Cytokinetics (NASDAQ: CYTK)The analyst comments "We’re reiterating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
